Schedule 1 - Medavinci plc (5842B)

TIDMZZZZ TIDMMVC
RNS Number : 5842B
AIM
21 February 2011
 
        ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION 
            IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES 
                                 ("AIM RULES") 
------------------------------------------------------------------------------ 
 
 COMPANY NAME: 
------------------------------------------------------------------------------ 
 Medavinci Plc (to be renamed Orogen Gold plc) 
------------------------------------------------------------------------------ 
 COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY 
  TRADING ADDRESS (INCLUDING POSTCODES) : 
------------------------------------------------------------------------------ 
 14 Kinnerton Place South, London, SW1X 8EH 
------------------------------------------------------------------------------ 
 COUNTRY OF INCORPORATION: 
------------------------------------------------------------------------------ 
 UK 
------------------------------------------------------------------------------ 
 COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED 
  BY AIM RULE 26: 
------------------------------------------------------------------------------ 
 www.medavinciplc.com (website to be updated from date of admission 
  to reflect change of name and change of business) 
------------------------------------------------------------------------------ 
 COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, 
  IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING 
  POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE 
  TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: 
------------------------------------------------------------------------------ 
 The admission is the result of a reverse takeover through the 
  acquisition by Medavinci plc of the remaining 51 per cent of 
  Orogen Gold limited that it does not already own. 
  The Company's previous investment strategy was to invest in 
  businesses in the UK and Europe which operate in mineral exploration 
  and production, support services, retail, media and healthcare 
  and which demonstrate the following criteria: 
  -- strong growth prospects, operating in sectors where demand 
  exceeds supply, where pricing and margin power can be established; 
  -- established management team with a proven track record; 
  and 
  -- capacity to benefit from being admitted to AIM. 
  Following the reverse takeover Orogen Gold will become the 
  Company's main trading subsidiary and the Company will move 
  from being an investing company to a holding company whose 
  main activities (via its subsidiaries) consist of exploring, 
  appraising, and developing gold deposits in Europe. 
------------------------------------------------------------------------------ 
 DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS 
  AS TO TRANSFER OF THE SECURITIES (i.e. where known, number 
  and type of shares, nominal value and issue price to which 
  it seeks admission and the number and type to be held as treasury 
  shares): 
------------------------------------------------------------------------------ 
 Admission of 315,351,636 new ordinary shares of 0.1p each and 
  readmission of 1,353,660,817 ordinary shares of 0.1p each. 
------------------------------------------------------------------------------ 
 CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED 
  MARKET CAPITALISATION ON ADMISSION: 
------------------------------------------------------------------------------ 
 No capital to be raised on admission. 
  Expected market capital on admission: GBP15.86 milliion 
------------------------------------------------------------------------------ 
 PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: 
------------------------------------------------------------------------------ 
 27.79% 
------------------------------------------------------------------------------ 
 DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH 
  THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES 
  (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED: 
------------------------------------------------------------------------------ 
 N/A 
------------------------------------------------------------------------------ 
 FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS 
  (underlining the first name by which each is known or including 
  any other name by which each is known): 
------------------------------------------------------------------------------ 
  Directors: 
   Adam Reynolds (Executive Chairman) 
   Paul Foulger (Finance Director) 
   Michael Nolan (Non-Executive Director) 
   Glyn Hirsch (Non-Executive Director) 
   Michael Hough (Non-Executive Director) 
   Proposed Directors: 
   John Barry (Non-Executive Chairman) 
   Edward Slowey (Chief Executive Officer) 
   Alan Mooney (Finance Director) 
  Upon Admission, Paul Foulger, Glyn Hirsch and Michael Hough 
  will stand down from the Board, Adam Reynolds will become a 
  non executive director and the Proposed Directors will be appointed 
  to the Board. 
------------------------------------------------------------------------------ 
 FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED 
  AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER 
  ADMISSION (underlining the first name by which each is known 
  or including any other name by which each is known): 
------------------------------------------------------------------------------ 
                                          % After 
   Name             % Before Admission   Admission 
   Michael 
    Hough                         7.94        6.44 
   Glyn Hirsch                    6.65        5.39 
    Adam                         8.20*       6.66* 
    Reynolds                     8.20*       6.66* 
    Paul 
    Foulger 
   Michael                        0.92        4.53 
    Nolan John                    1.39        6.79 
    Barry                         1.39        6.79 
    Edward                        0.92        4.53 
    Slowey                        9.23        7.49 
    Alan                          5.78        4.69 
    Mooney                        3.65        2.97 
    Anton 
    Bilton 
    David 
    Newton 
    Clare 
    Hughes 
  *The %s set out above with regard to Adam Reynolds and Paul 
  Foulger relate to the interests held by Wilton International 
  Marketing Limited and Diablo Consulting Limited. Wilton International 
  Marketing Limited holds 6.4% before admission (5.2% post admission) 
  of the issued share capital. Adam Reynolds holds 50 per cent. 
  and Paul Foulger holds 50 per cent. of the voting rights respectively 
  of Wilton International Marketing Limited. Diablo Consulting 
  Limited holds 1.8% before admission (1.5% after admission) 
  of the issued share capital. Adam Reynolds holds 29.9 per cent. 
  and Paul Foulger holds 70.1 per cent. of the voting rights 
  respectively of Diablo Consulting Limited. 
------------------------------------------------------------------------------ 
 NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 
  2, PARAGRAPH (H) OF THE AIM RULES: 
------------------------------------------------------------------------------ 
 N/A 
------------------------------------------------------------------------------ 
            (i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE 
            MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN 
            PREPARED (this may be represented by unaudited interim financial 
            information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE 
            REPORTS PURSUANT TO AIM RULES 18 AND 19: 
------------------------------------------------------------------------------ 
                  (i) 31 December 
                   (ii) 31 December 2010 
                   (iii) 30 September 2011, 30 June 2012, 30 September 2012 
------------------------------------------------------------------------------ 
 EXPECTED ADMISSION DATE: 
------------------------------------------------------------------------------ 
 7 March 2011 
------------------------------------------------------------------------------ 
 NAME AND ADDRESS OF NOMINATED ADVISER: 
------------------------------------------------------------------------------ 
 Zeus Capital Limited 
  3 Ralli Courts 
  West Riverside 
  Manchester M3 5FT 
------------------------------------------------------------------------------ 
 NAME AND ADDRESS OF BROKER: 
------------------------------------------------------------------------------ 
 Joint Brokers 
  Zeus Capital Limited 
  3 Ralli Courts 
  West Riverside 
  Manchester M3 5FT 
  XCAP Securities plc 
  24 Cornhill 
  London 
  EC3V 3ND 
------------------------------------------------------------------------------ 
 OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE 
  (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE 
  AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL 
  DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: 
------------------------------------------------------------------------------ 
 www.medavinciplc.com The admission document contains full details 
  about the company and the admission of its securities. 
------------------------------------------------------------------------------ 
 DATE OF NOTIFICATION: 
------------------------------------------------------------------------------ 
 21 February 2011 
------------------------------------------------------------------------------ 
 NEW/ UPDATE: 
------------------------------------------------------------------------------ 
 NEW 
------------------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
PAAEALAFAEKFEFF
Medavinci (LSE:MVC)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024